“We are extremely pleased with the support from the US NIH/NIAID and the clinical potential of our RVX-sCPD9 live-attenuated vaccine. This vaccine is based on our proprietary reverse genetics engineering platform technology (Viruflex™) and NIH will provide non-dilutive financial support for the advancement of our lead vaccine candidate,” said Vladimir Cmiljanović, Ph.D., Rocketvax’s Chief Executive Officer. “Partnership with the NIH/NIAID will advance the development of a next-generation SARS-CoV-2 vaccine platform into the clinical stage. Our lead candidate uses convenient nasal administration and, in animal studies, demonstrated high efficacy across viral strains, long-lasting protection, and the ability to prevent virus transmission. We believe that this clinical study will reinforce our efforts in extending the platform beyond SARS-CoV-2, focusing on infectious diseases, pandemic readiness, and cancer. We are committed to pushing the boundaries of vaccine design to improve global public health.”
About Rocketvax AG
Rocketvax AG, a pioneering biotech company and a member of the Swiss Rockets AG family of companies, is focused on developing next-generation vaccines using proprietary molecular biology technologies based on attenuated live viruses. Rocketvax`s vaccines are designed to offer broad protection and long-lasting immunity.
Our approach is rooted in a deep understanding of molecular biology and reverse genetic engineering, which enables us to develop vaccines that are not only safe and effective but also accessible to a wider population.
At Rocketvax, our mission is clear: to transform the landscape for infectious disease prevention through innovative vaccine development. We are dedicated to pushing the boundaries of vaccine design, with the goal of significantly improving global public health and making a meaningful impact on the lives of people around the world.
For more information, please visit our website at www.rocketvax.com or contact our press office at contact@rocketvax.com.